If You Invested in Matricelf (MTRLF)
Looking for the current price? See the MTRLF quote & overviewWhat $1,000 or $10,000 in MTRLF Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Feb 8, 2022 |
|---|---|---|---|---|
| $1,000 | — | — | — | $590 -41% |
| $10,000 | — | — | — | $5,901 -41% |
Based on real historical closing prices, dividend- and split-adjusted, through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for MTRLF$1,000 Investment Over Time
MTRLF vs S&P 500Year-by-Year Returns
MTRLF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2022 | $3.22 | $1.90 | -41.0% | -41.0% |
| 2023 | $1.90 | $1.90 | +0.0% | -41.0% |
| 2024 | $1.90 | $1.90 | +0.0% | -41.0% |
About Matricelf
Healthcare · OTC Link
Matricelf Ltd. (MTRLF) develops personalized regenerative medicine technologies for engineered neural tissue implants intended for spinal cord injury. The company is a biotechnology issuer whose public announcements identify its Tel Aviv Stock Exchange ticker as MTLF. Its operating focus is tissue engineering: using patient-specific biological material, stem-cell biology, and a proprietary human extracellular-matrix hydrogel platform to create three-dimensional neural tissue for potential implantation in damaged spinal cord tissue.
The company's lead application is a personalized spinal cord implant designed as an autologous therapy. Autologous approaches use a patient's own biological material, which Matricelf describes as a way to reduce the risk of implant rejection. The platform is also described as a broader method for personal three-dimensional printing of tissues and organs, although the company's current public development emphasis is on neural tissue for spinal cord injury.
Technology platform
Matricelf's technology combines neural tissue engineering with a hydrogel platform based on human extracellular matrix. Company announcements describe engineered neural tissues evaluated through cellular, genetic, protein-level, and functional measures, including neural marker expression and electrical activity. The company has reported safety characterization work using advanced RNA sequencing methods to examine the cellular composition of implant batches as part of its preclinical development program.
The technology originated from research associated with Tel Aviv University and was licensed to Matricelf under an exclusive global licensing agreement signed in 2019. Company materials also describe work connected to the Sagol Center for Regenerative Biotechnology at Tel Aviv University, including preclinical research involving engineered spinal cord tissues in chronic spinal cord injury models.
Development and manufacturing focus
Matricelf operates as a development-stage regenerative medicine company. Its recurring activities include preclinical safety and efficacy work, manufacturing process development, clinical-grade production planning, and collaboration with external research and technology organizations. The company has described a strategic collaboration with the CiRA Foundation in Japan to evaluate induced pluripotent stem cells in combination with Matricelf's proprietary neural tissue engineering platform. The stated objective of that work is to assess compatibility with automated, large-scale manufacturing approaches for engineered neural tissues.
Matricelf has also reported manufacturing-related research involving stem cells generated through artificial-intelligence-based technology in collaboration with Cellino Biotech. These activities fit the company's broader focus on translating personalized regenerative implants from laboratory-scale engineering into processes that could support regulated clinical development.
Corporate profile
Matricelf is based in Israel, and company announcements cite facilities in Ness Ziona. Its public communications center on regenerative medicine, spinal cord injury, personalized neural tissue implants, collaborations in stem-cell manufacturing, preclinical testing, and preparation for human clinical development. The company's profile is defined by its autologous tissue-engineering platform rather than by marketed pharmaceutical products or a diversified commercial portfolio.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Matricelf investment returns
How much would $1,000 invested in Matricelf be worth today?
Limited historical data is available for MTRLF. The stock has been trading since 2022-02-08.
Has Matricelf outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare MTRLF performance over available time periods.
What is Matricelf's average annual return?
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
